US FDA Asks Manufacturers To Fix Disruption In Isotretinoin REMS
Executive Summary
The agency offers ‘regulatory flexibility’ for certain requirements of the iPLEDGE REMS for the acne drug if manufacturers address delays in implementing the modified program.